Market research
PTN Palatin Technologies, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 53.5
- Dividend yield
- Not available
- Beta
- -0.01
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- 53.5
- Dividend yield
- Not available
- Beta
- -0.01
About
About Palatin Technologies, Inc. Common Stock
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases. licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
Research context
Palatin Technologies, Inc. Common Stock appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PTN discussion.
5 years, 6 months ago
Palatin Technologies, Inc is currently in a long term downtrend where the price is trading 6.5% below its 200 day moving average.
From a valuation standpoint, the stock is 40.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 792.2.
Palatin Technologies, Inc's total revenue sank by 895.6% to $-164K since the same quarter in the previous year.
Its net income has dropped by 90.6% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 189.3% to $-14M since the same quarter in the previous year.
Based on the above factors, Palatin Technologies, Inc gets an overall score of 1/5.